Antitumor activity of nintedanib (BIBF 1120), a triple angiokinase inhibitor, in combination with gemcitabine in experimental pancreatic cancer

被引：0
|
作者：
Awasthi, Niranjan [1 ]
Hinz, Stefan [2 ]
Brekken, Rolf A. [2 ]
Schwarz, Margaret A. [1 ]
Schwarz, Roderich E. [1 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
[2] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1025
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
    Cenik, Bercin Kutluk
    Ostapoff, Katherine T.
    Gerber, David E.
    Brekken, Rolf A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 992 - 1001
  • [2] BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
    Hilberg, Frank
    Roth, Gerald J.
    Krssak, Martin
    Kautschitsch, Susanna
    Sommergruber, Wolfgang
    Tontsch-Grunt, Ulrike
    Garin-Chesa, Pilar
    Bader, Gerd
    Zoephel, Andreas
    Quant, Jens
    Heckel, Armin
    Rettig, Wolfgang J.
    CANCER RESEARCH, 2008, 68 (12) : 4774 - 4782
  • [3] BIBF1120, an investigational triple angiokinase inhibitor, in combination with inhibitors of mTOR signaling shows potent antitumor activity in preclinical models of sarcoma
    Patwardhan, Parag P.
    Musi, Elgilda
    Ivy, Kathryn S.
    Giovino, Natalie
    Schwartz, Gary K.
    CANCER RESEARCH, 2014, 74 (19)
  • [4] BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer
    Rolfo, Christian
    Raez, Luis E.
    Bronte, Giuseppe
    Santos, Edgardo S.
    Papadimitriou, Kostantinos
    Buffoni, Lucio
    van Meerbeeck, Jan P.
    Russo, Antonio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (08) : 1081 - 1088
  • [5] Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity
    Tai, Wei-Tien
    Shiau, Chung-Wai
    Li, Yong-Shi
    Chang, Chun-Wei
    Huang, Jui-Wen
    Hsueh, Ting-Ting
    Chen, Kuen-Feng
    CANCER RESEARCH, 2014, 74 (19)
  • [6] Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity
    Tai, Wei-Tien
    Shiau, Chung-Wai
    Li, Yong-Shi
    Chang, Chun-Wei
    Huang, Jui-Wen
    Hsueh, Ting-Ting
    Yu, Hui-Chuan
    Chen, Kuen-Feng
    JOURNAL OF HEPATOLOGY, 2014, 61 (01) : 89 - 97
  • [7] In vitro and in vivo efficacy of BIBF 1120, a small molecule triple angiokinase inhibitor, in combination with taxanes.
    Hilberg, F
    Brandstetter, I
    Roth, GJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8969S - 8969S
  • [8] Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer
    Awasthi, Niranjan
    Hinz, Stefan
    Brekken, Rolf A.
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER LETTERS, 2015, 358 (01) : 59 - 66
  • [9] Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo
    Kudo, Kanae
    Arao, Tokuzo
    Tanaka, Kaoru
    Nagai, Tomoyuki
    Furuta, Kazuyuki
    Sakai, Kazuko
    Kaneda, Hiroyasu
    Matsumoto, Kazuko
    Tamura, Daisuke
    Aomatsu, Keiichi
    De Velasco, Marco A.
    Fujita, Yoshihiko
    Saijo, Nagahiro
    Kudo, Masatoshi
    Nishio, Kazuto
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1373 - 1381
  • [10] Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients
    Stopfer, P.
    Roth, W.
    Mross, K.
    Judson, I. R.
    Kienast, J.
    Kaiser, R.
    Stefanic, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 26 - 26
12345